

# Elena Cojocaru

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5854266/publications.pdf>

Version: 2024-02-01

11  
papers

444  
citations

1478280

6  
h-index

1281743

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploiting the folate receptor $\hat{\pm}$ in oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 349-359.	12.5	262
2	Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. <i>JCO Global Oncology</i> , 2020, 6, 1046-1051.	0.8	89
3	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
4	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , 2020, 6, 1-9.	0.8	20
5	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. <i>Medical Oncology</i> , 2020, 37, 13.	1.2	18
6	Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100737.	0.3	9
7	KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management. <i>Oncologist</i> , 2022, 27, 615-620.	1.9	6
8	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
9	Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. <i>European Journal of Cancer</i> , 2019, 114, 97-106.	1.3	4
10	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. <i>Anticancer Research</i> , 2020, 40, 7003-7007.	0.5	3
11	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 23-35.	0.6	1